NOVOEIGHT 1500 IU

국가: 이스라엘

언어: 영어

출처: Ministry of Health

지금 구매하세요

Download 환자 정보 전단 (PIL)
02-04-2019
Download 제품 특성 요약 (SPC)
17-02-2019
Download 공공 평가 보고서 (PAR)
17-02-2019

유효 성분:

TUROCTOCOG ALFA

제공처:

NOVO NORDISK LTD, ISRAEL

ATC 코드:

B02BD02

약제 형태:

POWDER AND SOLVENT FOR SOLUTION FOR INJECTION

구성:

TUROCTOCOG ALFA 1500 IU / 4 ML

관리 경로:

I.V

처방전 유형:

Required

Manufactured by:

NOVO NORDISK A/S, DENMARK

치료 영역:

COAGULATION FACTOR VIII

치료 징후:

Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency).NovoEight can be used for all age groups.

승인 날짜:

2015-09-21

제품 특성 요약

                                1
The content of this leaflet was approved by the Ministry of Health in
September 2015 and updated
according to the guidelines of the Ministry of Health in January 2019
1.
NAME OF THE MEDICINAL PRODUCT
NovoEight 250 IU powder and solvent for solution for injection
NovoEight 500 IU powder and solvent for solution for injection
NovoEight 1000 IU powder and solvent for solution for injection
NovoEight 1500 IU powder and solvent for solution for injection
NovoEight 2000 IU powder and solvent for solution for injection
NovoEight 3000 IU powder and solvent for solution for injection
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
NovoEight 250 IU powder and solvent for solution for injection.
Each powder vial contains nominally 250 IU human coagulation factor
VIII (rDNA), turoctocog alfa.
After reconstitution NovoEight contains approximately 62.5 IU/ml of
human coagulation factor VIII
(rDNA), turoctocog alfa.
NovoEight 500 IU powder and solvent for solution for injection.
Each powder vial contains nominally 500 IU human coagulation factor
VIII (rDNA), turoctocog alfa.
After reconstitution NovoEight contains approximately 125 IU/ml of
human coagulation factor VIII
(rDNA), turoctocog alfa.
NovoEight 1000 IU powder and solvent for solution for injection.
Each powder vial contains nominally 1000 IU human coagulation factor
VIII (rDNA), turoctocog alfa.
After reconstitution NovoEight contains approximately 250 IU/ml of
human coagulation factor VIII
(rDNA), turoctocog alfa.
NovoEight 1500 IU powder and solvent for solution for injection.
Each powder vial contains nominally 1500 IU human coagulation factor
VIII (rDNA), turoctocog alfa.
After reconstitution NovoEight contains approximately 375 IU/ml of
human coagulation factor VIII
(rDNA), turoctocog alfa.
NovoEight 2000 IU powder and solvent for solution for injection.
Each powder vial contains nominally 2000 IU human coagulation factor
VIII (rDNA), turoctocog alfa.
After reconstitution NovoEight contains approximately 500 IU/ml of
human coagulation factor VIII
(rDNA), turoctocog
                                
                                전체 문서 읽기
                                
                            

다른 언어로 된 문서

환자 정보 전단 환자 정보 전단 아랍어 15-07-2019
환자 정보 전단 환자 정보 전단 히브리어 15-07-2019

이 제품과 관련된 검색 알림